Quality

Clinical Research: Phase 1 - Phase 4

Managing the Placebo Problem in Chronic Pain Studies

Placebo response is a widespread and growing challenge in clinical drug studies for analgesics. Pain assessments are generally subjective to the patient and may be influenced by misunderstanding of the assessment criteria, exaggerated expectations, subconscious desire to please investigators whom patients come to trust as allies, and other factors. As the effect size gets smaller...

Data Management & Biostatistics

ICH GCP Update: Sponsor Control of Clinical Trial Data

Under the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP), sponsors have extensive responsibilities for ensuring not only the ethical and scientific quality of clinical trials, but also the protection of study participants and the integrity of clinical trial data. The recent update of...

Medical and Regulatory Affairs

ICH GCP E6 (R2): A Primer for Small Biotech and Specialty Pharma Companies

Recent updates to the ICH Good Clinical Practice guidelines call for implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting that are intended to increase clinical trial quality and efficiency while continuing to ensure human subject protection and data integrity. Now, biotech and specialty pharma innovators face even...

Consulting

The Placebo Problem, Part 15: Ethical Considerations

This is the fifteenth and final installment of our look at the increasingly high placebo response that is plaguing clinical trials in analgesia and psychiatry. Read the rest of the posts in the series here. As our Placebo Problem series draws to a close, we conclude by taking a brief look at three ethical issues...

Consulting

Pharma Quality Agreements: What Are They, and Why They Matter For Your Study

Quality Agreements are an effective bridge to a successful future for companies in the drug development sector – putting one in place at the start of the business relationship can prevent problems later. Quality Agreements mitigate risk and increase collaboration between partners. These agreements define timelines and establish responsibility and accountability. They supplement contractual commitments....

Consulting

Clinical Endpoint Committees: Ensuring the Quality, Validity, and Integrity of Clinical Trial Results

The use of Clinical Endpoint Committees for centralized adjudication of efficacy and/or safety endpoints can help to standardize outcomes and optimize the quality of clinical trial data, driving study success. Some compounds and many devices face the challenge of defining efficacy or safety endpoints so that they are scientifically measurable, objective, and valid. Often, clinical...

Data Management & Biostatistics

Endpoint Data Capture Strategy: 4 Questions for Sponsors

For a Clinical Endpoint Committee (CEC) to make important decisions, it needs the data to do so. That’s why developing an effective and reliable endpoint data capture strategy is a vital part of working with a CEC. Before starting a clinical trial, sponsors should be able to answer these questions. 1. What needs to be defined?...

Clinical Research: Phase 1 - Phase 4

8 Steps to Jump-Starting a CEC

In our previous CECs blogpost, we reviewed why Clinical Endpoint Committees (CECs) are so crucial for successful trials today. But just how do sponsors establish and operate a CEC? It’s a complex process that can be broken down into these eight key steps: 1. Understand the deep level of commitment required in putting a CEC together....

Quality

Quality Assurance VP Speaking at Life Sciences Webcast July 20

DURHAM, N.C., June 29, 2017 — Premier Research’s head of quality assurance will speak on life sciences supplier certification during a webcast hosted by The Knowledge Group. The event takes place Thursday, July 20, from 3 p.m. to 5 p.m. Eastern. The Life Sciences’ Supplier and Contractor Qualification and Control Framework Explored will address challenges...

Data Management & Biostatistics

Quality Expert to Discuss Data Integrity at DIA Annual Meeting

DURHAM, N.C., June 19, 2017 — Data integrity has been a prime focus of pharmaceutical regulators for two decades now, but the focus is sharpening markedly with issuance of new guidance from multiple regulatory authorities. Sherri Hubby, who leads quality assurance, risk, and compliance at Premier Research, will address this trend and its implications at...